Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company, announced it will release its Q2 2025 financial results and corporate updates after market close on Thursday, August 7, 2025.
The company, which specializes in combining computational and experimental technologies for drug discovery, will provide details on its financial performance and business progress.
Relay Therapeutics (NASDAQ:RLAY), un'azienda di medicina di precisione in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2025 e aggiornamenti aziendali dopo la chiusura del mercato di giovedì 7 agosto 2025.
L'azienda, specializzata nella combinazione di tecnologie computazionali e sperimentali per la scoperta di farmaci, fornirà dettagli sulle sue performance finanziarie e sui progressi aziendali.
Relay Therapeutics (NASDAQ:RLAY), una compañía de medicina de precisión en etapa clínica, anunció que publicará sus resultados financieros del segundo trimestre de 2025 y actualizaciones corporativas después del cierre del mercado el jueves 7 de agosto de 2025.
La empresa, que se especializa en combinar tecnologías computacionales y experimentales para el descubrimiento de medicamentos, brindará detalles sobre su desempeño financiero y avances comerciales.
Relay Therapeutics (NASDAQ:RLAY)는 임상 단계 정밀 의학 회사로서 2025년 8월 7일 목요일 장 마감 후 2025년 2분기 재무 실적 및 기업 업데이트를 발표할 예정입니다.
이 회사는 약물 발견을 위해 계산 기술과 실험 기술을 결합하는 데 전문성을 가지고 있으며, 재무 성과와 사업 진행 상황에 대한 세부 정보를 제공할 것입니다.
Relay Therapeutics (NASDAQ:RLAY), une société de médecine de précision en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2025 et des mises à jour corporatives après la clôture du marché le jeudi 7 août 2025.
La société, spécialisée dans la combinaison de technologies computationnelles et expérimentales pour la découverte de médicaments, fournira des détails sur ses performances financières et ses avancées commerciales.
Relay Therapeutics (NASDAQ:RLAY), ein klinisch tätiges Präzisionsmedizin-Unternehmen, gab bekannt, dass es seine Finanzergebnisse für das zweite Quartal 2025 und Unternehmensupdates nach Börsenschluss am Donnerstag, den 7. August 2025 veröffentlichen wird.
Das Unternehmen, das sich auf die Kombination von computergestützten und experimentellen Technologien zur Wirkstoffforschung spezialisiert hat, wird Einzelheiten zu seiner finanziellen Leistung und dem Geschäftserfolg bekanntgeben.
- None.
- None.
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 7, 2025.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) report Q2 2025 earnings?
What is Relay Therapeutics' (RLAY) main business focus?
How can investors access Relay Therapeutics' Q2 2025 earnings report?
What stock exchange is Relay Therapeutics (RLAY) listed on?
